Canadian clinical-stage pharmaceutical company Tryp Therapeutics has received shareholder approval to merge with Exopharm and operate under a combined entity. In December 2023 , Exopharm entered a definitive agreement to acquire all outstanding shares of Tryp Therapeutics. The transaction is to close by May 1, 2024, subject to conditions.
After the merger, Tryp intends to continue advancing its pipeline of psilocin-based therapies. The merger is expected to provide the company with increased visibility and access to a more extensive investor base.
Furthermore, the merged entity will be known as "Tryptamine Therapeutics Limited" and will commence trading on the Australian Securities Exchange under the ticker symbol "TYP" from May 15, 2024, subject to necessary approvals and conditions.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.